Follow DNDi on FacebookFollow DNDi on TwitterFollow DNDi on LinkedInrss Donate Now to DNDi

News

2016: Year in Review

Our staff, partners, and stakeholders share their highlights from 2016.

African Eye Worm:"Worse than it looks."

New study shows that the disease leads to increased mortality and highlights R&D gap for filarial diseases. Link here.

UN High-Level Meeting on Antimicrobial Resistance

DNDi Welcomes the Political Declaration of the United Nations High-Level Meeting on Antimicrobial Resistance. Our statement is here.

Busting the Billion Dollar Myth

Click here to read Amy Maxmen's feature on DNDi in Nature magazine, "Busting the billion-dollar myth: how to slash the cost of drug development."

Towards Ending the Neglected on Pediatric HIV

In advance of the International AIDS Conference in Durban, we launched an update on our efforts to develop better HIV medicines for children.

First US-Based Company Joins Drug Booster

Celgene joins DNDi’s “Drug Discovery Booster” to accelerate discovery of new treatments for neglected diseases. Release here

"Hepatitis C treatment for under $300 coming soon"

The Guardian on the launch of our project to develop an affordable hepatitis C regimen.

"The Zika loopholes"

We join MSF, TB Alliance in others in calling Priority Review Voucher Reform in Politico.

World Lymphedema Day Designated by US Senate

Will Raise Awareness of 40 Million Suffering from Elephantiasis. Our statement.

"A Disease So Neglected It's Not Even On 'Most-Neglected' Lists"

NPR "Goats and Soda" on efforts to finally tackle Mycetoma. Article here!

Untold Global Health Story of 2015: Mycetoma

Don't miss journalist Amy Maxmen's three-part series on the world's most neglected disease. Exclusive from Global Health NOW.

DNDi Statement on KaloBios’ Intention to Raise Price of Chagas Drug and File for FDA Priority Review

Please read our statement here
As reported in the New York Times & Atlantic.

DNDi Calls for Priority Review Voucher Program Reform

Our call for reform in Politico & STAT!

Going further for Filarial disease patients

Our PLOS Speaking of Medicines blog on our efforts to develop new drugs for river blindness and lymphatic filariasis.

2015-2023 Business Plan

DNDi unveils new plan for neglected patients. Read more here.